Advertisement

Chimeric antigen receptor (CAR) T therapy and cognitive functions

Published:November 15, 2022DOI:https://doi.org/10.1016/j.jns.2022.120495

      Highlights

      • Chimeric antigen receptor (CAR) T-cell therapy is a revolutionary therapeutic breakthrough for certain cancers.
      • The potential effect of CAR T therapy on cognitive functions is a concern.
      • Findings from current studies have shown varied results.
      • Some studies have suggested that the adverse effects on cognition are potentially reversible.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of the Neurological Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Hoogland A.I.
        • Barata A.
        • Logue J.
        • et al.
        Change in neurocognitive performance among patients with non-Hodgkin lymphoma in the first year after chimeric antigen receptor T cell therapy.
        Transplant Cell Ther. 2022; 28: 305.e1-305.e9
        • Möhn N.
        • Bonda V.
        • Grote-Levi L.
        • et al.
        Neurological management and work-up of neurotoxicity associated with CAR T cell therapy.
        Neurol. Res. Pract. 2022; 4: 1
        • Belin C.
        • Devic P.
        • Ayrignac X.
        • et al.
        Description of neurotoxicity in a series of patients treated with CAR T-cell therapy.
        Sci. Rep. 2020; 10: 18997
        • Ruark J.
        • Mullane E.
        • Cleary N.
        • et al.
        Patient-reported neuropsychiatric outcomes of long-term survivors after chimeric antigen receptor T cell therapy.
        Biol. Blood Marrow Transplant. 2020; 26: 34-43
        • Shalabi H.
        • Wolters P.L.
        • Martin S.
        • et al.
        Systematic evaluation of neurotoxicity in children and young adults undergoing CD22 chimeric antigen receptor-T cell therapy.
        J. Immunother. 2018; 41: 350-358
        • Maillet D.
        • Belin C.
        • Moroni C.
        • et al.
        Evaluation of mid-term (6-12 months) neurotoxicity in B-cell lymphoma patients treated with CAR T cells: a prospective cohort study.
        Neuro-Oncology. 2021; 23: 1569-1575
        • Cheng C.
        • Scippa K.
        • Locke F.L.
        • Snider J.T.
        • Jim H.
        Patient perspectives on health-related quality of life in diffuse large B-cell lymphoma treated with Car T-cell therapy: a qualitative study.
        Oncol. Ther. 2022; 10: 123-141
        • Wang X.S.
        • Srour S.A.
        • Whisenant M.
        • et al.
        Patient-reported symptom and functioning status during the first 12 months after chimeric antigen receptor T cell therapy for hematologic malignancies.
        Transplant Cell Ther. 2021; 27: 930.e1-930.e10
        • Tan B.B.J.
        • Chan L.L.
        • Tan E.K.
        Perceived cognitive changes following chimeric antigen receptor T cell therapy in lymphoma: perceptual anticipation?.
        Transplant Cell Ther. 2022; S2666-6367 (01628–1)
        • Liu H.L.
        • Deng B.
        • Zhou H.
        • et al.
        QEEG indices are associated with inflammatory and metabolic risk factors in Parkinson’s disease dementia: an observational study.
        EClinicalMedicine. 2022; 52: 101615https://doi.org/10.1016/j.eclinm.2022.101615
        • Yang Q.
        • Wei X.B.
        • Deng B.
        • et al.
        Cerebral small vessel disease alters neurovascular unit regulation of microcirculation integrity involved in vascular cognitive impairment.
        Neurobiol. Dis. 2022; 170: 105750
        • Zhu S.Z.
        • Wei X.B.
        • Yang X.H.
        • et al.
        Lipoprotein-associated phospholipase A2 and superoxide dismutase are independent predicators of cognitive impairment in cerebral small vessel disease patients: diagnosis and assessment.
        Aging Dis. 2019; 10: 834-846